Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 1 14Phase 3 8Phase NA 5Phase 1/2 3Phase 4 2

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Plasma cell 1Lymphoid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 82Neoplasms 78Colorectal Neoplasms 67Neoplasm Metastasis 65Prostatic Neoplasms 61Leukemia, Myeloid, Acute 61Ovarian Neoplasms 57Recurrence 55Pancreatic Neoplasms 55Multiple Myeloma 52Melanoma 40Triple Negative Breast Neoplasms 36Lung Neoplasms 36Glioblastoma 36Squamous Cell Carcinoma of Head and Neck 34Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 26Myelodysplastic Syndromes 25Lymphoma, B-Cell 25Advanced Solid Tumor 25Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24

Interventions

fludarabine phosphate 1asciminib 1Whole-Body Irradiation 1Sirolimus 1Mycophenolic Acid 1Melphalan 1Cyclophosphamide 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 90 days × Clear all
NCT02629692 2026-05-13

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Sun Pharma Advanced Research Company Limited

Phase 1/2 Terminated
124 enrolled 51 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04925479 2026-04-30

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Novartis

Phase 1/2 Recruiting
34 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡